SDS-PAGE separation of QP8910 followed by commassie total protein stain results in a primary band consistent with reported data for HLA-DRA. These data demonstrate Greater than 90% as determined by SDS-PAGE.

Recombinant Human HLA-DRA Protein

$ 448.00$ 1,938.00
Please Select Product Options Below To View The Catalog Number.

SKU: QP8910
Species: Human
Available Tags: His
Host: E. coli
Purity: Greater than 90% as determined by SDS-PAGE.
Length (Amino Acids): 227

Product NumberDescriptionPrice
QP8910-ec-100ug Size: 100 ug, Tag: His $ 448.00
QP8910-ec-1mg Size: 1 mg, Tag: His $ 1,938.00
Shipping Information
On Demand Protein: 3-5 Week Lead Time. (Why?)
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QP8910-ec-10ug
Recombinant Human HLA-DRA Protein (28-254aa) General Information
Alternate Names
HLA-DRA; HLA-DRA1
Curated Database and Bioinformatic Data
Gene SymbolHLA-DRA
Entrez Gene ID3122
Ensemble Gene IDENSG00000227993
RefSeq Protein Accession(s)NP_061984.2
RefSeq mRNA Accession(s)NM_019111.4
UniProt ID(s)P01903
UniGene ID(s)Hs.520048
HGNC ID(s)HGNC:4947
COSMIC ID Link(s)HLA-DRA
KEGG Gene ID(s)hsa:3122
PharmGKB ID(s)PA35071
General Description of Recombinant Human HLA-DRA Protein (28-254aa).
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents th on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As mbrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal syst where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The roval of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell mbrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Human HLA-DRA Recombinant Protein Product Attributes

Product Type: Recombinant Protein
Recombinant HLA-DRA based upon sequence from: Human
Host: QP8910 protein expressed in E. coli.
Tag: His
Protein Construction: A DNA sequence encoding the Homo sapiens (Human) HLA-DRA, was expressed in the hosts and tags indicated. Please select your host/tag option, above.
Application Notes: Please contact us for application specific information for QP8910.
Bioactivity Data: Untested
Full Length? Full Length
Expression Region: Glu28 - Leu254
Amino Acid Sequence: EEHVIIQAEF YLNPDQSGEF MFDFDGDEIF HVDMAKKETV WRLEEFGRFA SFEAQGALAN IAVDKANLEI MTKRSNYTPI TNVPPEVTVL TNSPVELREP NVLICFIDKF TPPVVNVTWL RNGKPVTTGV SETVFLPRED HLFRKFHYLP FLPSTEDVYD CRVEHWGLDE PLLKHWEFDA PSPLPETTEN VVCALGLTVG LVGIIIGTIF IIKGVRKSNA AERRGPL
Purity: Greater than 90% as determined by SDS-PAGE.
Reconstitution Instructions:
Concentration of Human HLA-DRA Protein:
Endotoxin Levels: Not determined.
Buffer: Tris-based buffer, 50% glycerol
Storage Conditions: Store at -20C to -80C.

Limitations and Performance Guarantee

This is a life science research product (for Research Use Only). This product is guaranteed to work for a period of two years when stored at -70C or colder, and one year when aliquoted and stored at -20C.

There are no reviews yet.

Be the first to review “Recombinant Human HLA-DRA Protein”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Recombinant Human HLA-DRA Protein